The role of active brown adipose tissue in human metabolism

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 43, Issue 2, 2016, Pages 355-361

  Ozguven, Salih ^a   Ones, Tunc ^a,b   Yilmaz, Yusuf ^a   Turoglu, H Turgut ^a   Imeryuz, Nese ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b Kayasultan Sokak   (Turkey)

Author keywords

18F Fluorodeoxyglucose; Adipose tissue, brown; Dyslipidaemias; Non alcoholic fatty liver disease; Positron emission tomography

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FLUORODEOXYGLUCOSE F 18; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; RADIOPHARMACEUTICAL AGENT;

ACTIVATED BROWN ADIPOSE TISSUE; ADULT; ARTICLE; BLOOD SAMPLING; BROWN ADIPOSE TISSUE; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; LIPID BLOOD LEVEL; LIVER; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLISM; NONALCOHOLIC FATTY LIVER; RETROSPECTIVE STUDY; SPLEEN; TRIACYLGLYCEROL BLOOD LEVEL; DIAGNOSTIC IMAGING; DYSLIPIDEMIAS; MIDDLE AGED; MULTIMODAL IMAGING; NON-ALCOHOLIC FATTY LIVER DISEASE; POSITRON EMISSION TOMOGRAPHY; X-RAY COMPUTED TOMOGRAPHY;

ADIPOSE TISSUE, BROWN; ADULT; DYSLIPIDEMIAS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NON-ALCOHOLIC FATTY LIVER DISEASE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84952987693     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-015-3166-7     Document Type: Article

References (25)

1. Heeren J, Munzberg H. Novel aspects of brown adipose tissue biology. Endocrinol Metab Clin North Am. 2013;42:89–107.
2. Tews D, Wabitsch M. Renaissance of brown adipose tissue. Horm Res Paediatr. 2011;75:231–9.
3. Bauwens M, Wierts R, van Royen B, Bucerius J, Backes W, Mottaghy F, et al. Molecular imaging of brown adipose tissue in health and disease. Eur J Nucl Med Mol Imaging. 2014;41:776–91.
4. Van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JM, Kemerink GJ, Bouvy ND, et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med. 2009;360:1500–8.
5. Yilmaz Y, Ones T, Purnak T, Ozguven S, Kurt R, Atug O, et al. Association between the presence of brown adipose tissue and non-alcoholic fatty liver disease in adult humans. Aliment Pharmacol Ther. 2011;34:318–23.
6. Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, Peldschus K, et al. Brown adipose tissue activity controls triglyceride clearance. Nat Med. 2011;17:200–5.
7. Khedoe PP, Hoeke G, Kooijman S, Dijk W, Buijs JT, Kersten S, et al. Brown adipose tissue takes up plasma triglycerides mostly after lipolysis. J Lipid Res. 2015;56:51–9.
8. Pfannenberg C, Werner MK, Ripkens S, Stef I, Deckert A, Schmadl M, et al. Impact of age on the relationships of brown adipose tissue with sex and adiposity in humans. Diabetes. 2010;59:1789–93.
9. Perkins AC, Mshelia DS, Symonds ME, Sathekge M. Prevalence and pattern of brown adipose tissue distribution of 18F-FDG in patients undergoing PET-CT in a subtropical climatic zone. Nucl Med Commun. 2013;34:168–74.
10. Ricci C, Longo R, Gioulis E, Bosco M, Pollesello P, Masutti F, et al. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol. 1997;27:108–13.
11. Kodama Y, Ng CS, Wu TT, Ayers GD, Curley SA, Abdalla EK, et al. Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol. 2007;5:1307–12.
12. Hong EP, Park JW. Sample size and statistical power calculation in genetic association studies. Genomics Inform. 2012;10:117–22.
13. Ouellet V, Routhier-Labadie A, Bellemare W, Lakhal-Chaieb L, Turcotte E, Carpentier AC, et al. Outdoor temperature, age, sex, body mass index, and diabetic status determine the prevalence, mass, and glucose-uptake activity of 18F-FDG-detected BAT in humans. J Clin Endocrinol Metab. 2011;96:192–9.
14. Vijgen GH, Bouvy ND, Teule GJ, Brans B, Hoeks J, Schrauwen P, et al. Increase in brown adipose tissue activity after weight loss in morbidly obese subjects. J Clin Endocrinol Metab. 2012;97:1229–33.
15. Jacene HA, Cohade CC, Zhang Z, Wahl RL. The relationship between patients’ serum glucose levels and metabolically active brown adipose tissue detected by PET/CT. Mol Imaging Biol. 2011;13:1278–83.
16. Saito M, Okamatsu-Ogura Y, Matsushita M, Watanabe K, Yoneshiro T, Nio-Kobayashi J, et al. High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes. 2009;58:1526–31.
17. Souza MR, Diniz Mde F, Medeiros-Filho JE, Araujo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol. 2012;49:89–96.
18. Zhang Q, Ye H, Miao Q, Zhang Z, Wang Y, Zhu X, et al. Differences in the metabolic status of healthy adults with and without active brown adipose tissue. Wien Klin Wochenschr. 2013;125:687–95.
19. Szlosarek P, Charles KA, Balkwill FR. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer. 2006;42:745–50.
20. Das SK, Hoefler G. The role of triglyceride lipases in cancer associated cachexia. Trends Mol Med. 2013;19:292–301.
21. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25:883–9.
22. Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;28:503–22.
23. Almeda-Valdés P, Cuevas-Ramos D, Aguilar-Salinas CA. Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol. 2009;8:18–24.
24. Lonardo A, Lombardini S, Ricchi M, Scaglioni F, Loria P. Review article: hepatic steatosis and insulin resistance. Aliment Pharmacol Ther. 2005;22:64–70.
25. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–73.